The Relationship among Pore-Size Ratings, Bubble Points, and Porosity - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Relationship among Pore-Size Ratings, Bubble Points, and Porosity

Pharmaceutical Technology

The wet testing involved is usually proprietary. Presumably, the test values of any of the integrity tests, including the forward flow, based on diffusive airflows, may be serving this purpose. Experimentally determined bubble points are the guiding measuring units known to the authors to be used. Although the membrane is classified in terms of pore-size ratings, the category is determined on the basis of bubble-point values. The higher the bubble-point value, the smaller the pore-size rating and the more likely the retention of smaller organisms. The grouping by bubble point inexorably gives rise to a spectrum of values for each pore-size rating.

Care is taken that membranes intended for sterilization filtrations are not of too low a bubble-point value; this would signify a too open pore arrangement susceptible to organism passage. On the other hand, tighter filters are seen as a guarantee against violating the threshold value that was experimentally established as being capable of removing 1 107 cfu of B. diminuta per square centimeter of EFA. In fact, in a responsible address to dependable quality membrane, manufacturers add a (nonstandard) safety margin to the threshold value of the product that is released to the market.

Figure 9: Correlation of bubble points and organism retention.
After meeting the bubble-point requirements and the ASTM bacterial challenge test, the filters intended for sterilizing applications are labeled as being of the 0.2/0.22 μm pore-size rating. No industry standards guide the filter purveyor. Each manufacturer is free to use the numbers and limits he considers appropriate. The bubble-point value set by the filter manufacturer for his filter, whether with safety margin or not, is considered the defining number by FDA investigators. It is beyond questioning by the filter users. Pharmaceutical houses, however, may develop and validate their own LRV–bubble point correlations for the filters they use. This is accepted by regulators.

Bubble point, organism retention

The bubble point had been shown by several experimenters to correlate directly with the log reduction values (LRV) characteristic of a given filter type confronted by a particular type organism (25, 41–43) (see Figure 9). B. diminuta ATCC 19146 was the organism whose different degrees of retention, expressed as LRVs, was shown to correspond to specific bubble-point pressure levels. Establishing the capability of a filter to sustain a challenge level of 1 107 cfu of B. diminuta per cm2 of efa, expressed as its bubble point, defines its qualification as a "sterilizing filter." This performance accords with FDA's definition of a sterilizing filter (2). The following equation describes the relationship of the bubble point to the pore's diameter, the dimension most influential on its retention properties:

in which θ represents the angle of wetting, λ is the liquid's surface tension, D signifies the pore diameter, and P is the bubble-point pressure in psi.

The equation is correct in indicating the reciprocal relationship of the bubble-point pressure with the restrictive pore width. The critical sensitivity of the wetting action, however, disallows calculating the dimensional size of the pore by way of the equation. Obtaining retentions of 1 107 /cm2 requires more than a particular pore-size rating. It is dependent also on the suspending fluid's compatibility with both organisms and filter in terms of size alterations of the microbes and pores; on the filtration conditions, especially the differential pressure, temperature and viscosity; and on the numbers, shapes, and size distributions of both the pores and the organisms.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here